<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00881296</url>
  </required_header>
  <id_info>
    <org_study_id>Hamamatsu 20-34</org_study_id>
    <nct_id>NCT00881296</nct_id>
  </id_info>
  <brief_title>Gemcitabine and Carboplatin for Elderly Patient With Lung Cancer</brief_title>
  <acronym>GEEP</acronym>
  <official_title>Randomized Phase II Study of Biweekly Chemotherapy With Gemcitabine and Carboplatin in Elder Patients With Previously Untreated Advanced Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hamamatsu University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hamamatsu University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A comparison of biweekly combination chemotherapy (gemcitabine plus carboplatin) with weekly
      gemcitabine in elder patients (&gt; 75) with previously untreated advanced non-small cell lung
      cancer. Primary objective is to determine the objective response rate (CR+PR by RECIST
      criteria) for biweekly gemcitabine and carboplatin combination chemotherapy versus weekly
      single gemcitabine as first-line therapy in elder advanced non-small lung cancer patients (&gt;
      76 years) who have received no prior treatment for non-small lung cancer. As secondary
      objectives, adverse event profile, tolerability of biweekly gemcitabine and carboplatin
      combination chemotherapy, progression-free survival and overall survival will be evaluated in
      both patients with biweekly gemcitabine and carboplatin combination chemotherapy and weekly
      single gemcitabine.

      The study hypothesis is that biweekly combination chemotherapy of gemcitabine plus
      carboplatin may improve the efficacy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy (response rate)</measure>
    <time_frame>two-years, followed RECIST criteria</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The toxicity profile (adverse event profile)</measure>
    <time_frame>two-years, followed NCI-CTCAE criteria</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Non-Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gemcitabine 1000mg/m2 Day 1,15
Carboplatin AUC=3 Day 1, 15 every 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Gemcitabine 1000mg/m2 Day 1, 8, 15</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine and carboplatin</intervention_name>
    <description>Gemcitabine 1000mg/m2, DIV on day 1 and 15 of each 28 day cycle. Carboplatin AUC=3, DIV on day 1 and 15 of each 28 day cycle. Number of cycles: until progression or unacceptable toxicity develops, up to 6 cycles.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Gemcitabine 1000mg/m2, DIV on day 1, 8 and 15 of each 28 day cycle. Number of cycles: until progression or unacceptable toxicity develops, up to 6 cycles</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of histologically confirmed stage IIIB or IV non-small cell lung cancer

          -  Good performance status (ECOG 0-1)

          -  No previous treatment

          -  Age 76 years and older

          -  Adequate bone marrow, liver and renal functions

          -  No pregnant

          -  Measurable disease, defined as at least one lesion whose longest diameter can be
             accurately measured as &gt;=1.0 cm by spiral CT scan

          -  Provided written informed consent

        Exclusion Criteria:

          -  Severe complications or a concomitant malignancy

          -  Prior and other concurrent radiotherapy, chemotherapy, immunotherapy, EGFR tyrosine
             kinase inhibitors

          -  Interstitial pneumonia or lung fibrosis

          -  Contraindicated gemcitabine or carboplatin

          -  Inappropriate patients for entry to this study, judged by the physicians
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>76 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kingo Chida, MD,PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Hamamatsu University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hamamatsu University School of Medicine</name>
      <address>
        <city>Hamamatsu</city>
        <state>Shizuoka</state>
        <zip>431-3192</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>May 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 14, 2009</study_first_submitted>
  <study_first_submitted_qc>April 14, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 15, 2009</study_first_posted>
  <last_update_submitted>September 5, 2011</last_update_submitted>
  <last_update_submitted_qc>September 5, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 7, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hamamatsu University</investigator_affiliation>
    <investigator_full_name>Naoki Inui</investigator_full_name>
    <investigator_title>Department of Respiratory Medicine</investigator_title>
  </responsible_party>
  <keyword>Elder Patients</keyword>
  <keyword>Non-Small Cell Lung Cancer</keyword>
  <keyword>Previously Untreated</keyword>
  <keyword>Advanced</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

